From clinical trials to clinical practice: Therapeutic cancer vaccines for the treatment of prostate cancer

Expert Review of Vaccines

Volumn 10, Issue 6, 2011, Pages 743-753

  Madan, Ravi A ^a   Aragon Ching, Jeanny B ^a   Gulley, James L ^a   Dahut, William L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

castration resistant; metastatic; prostate cancer; therapeutic cancer vaccine; treatment

Indexed keywords

ABIRATERONE; ABIRATERONE ACETATE; ACID PHOSPHATASE PROSTATE ISOENZYME; ANDROGEN RECEPTOR ANTAGONIST; CABAZITAXEL; CANCER VACCINE; DOCETAXEL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IPILIMUMAB; KETOCONAZOLE; MITOXANTRONE; PLACEBO; PREDNISOLONE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; PROSTVAC; PROVENGE; PSA TRICOM VACCINE; UNCLASSIFIED DRUG;

ANDROGEN DEPRIVATION THERAPY; ANTINEOPLASTIC ACTIVITY; AUTOIMMUNE DISEASE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL THERAPY; CHILL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; DRUG FATALITY; ACETATE; DRUG FEVER; DRUG MECHANISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; FATIGUE; FLU LIKE SYNDROME; HUMAN; INJECTION SITE REACTION; MELANOMA; METASTASIS; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; REVIEW; SYMPTOMATOLOGY; TREATMENT OUTCOME; TUMOR IMMUNITY; UNSPECIFIED SIDE EFFECT;

CANCER VACCINES; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; MALE; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS; TISSUE EXTRACTS; TREATMENT OUTCOME;

EID: 79959572215     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.11.70     Document Type: Review

References (77)

1. Huggins C, Bergenstal DM. Inhibition of human mammary and prostatic cancers by adrenalectomy. Cancer Res. 12(2), 134-141 (1952
2. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA 294(2), 238-244 (2005 (Pubitemid 41043794)
3. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351(15), 1502-1512 (2004 (Pubitemid 39315317)
4. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 351(15), 1513-1520 (2004 (Pubitemid 39315318)
5. Tran C, Ouk S, Clegg NJ et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324(5928), 787-790 (2009
6. Madan RA, Arlen PM. Abiraterone. Cougar Biotechnology. IDrugs 9(1), 49-55 (2006 (Pubitemid 43135698)
7. De Bono J, Logothetis C, Fizazi K et al. Abiraterone acetate (AA) plus low dose prednisone (P) improves overall survival (OS) in patients (PTS) with metastatic castration-resistant prostate cancer (mCRPC) who have progressed after docetaxel-based chemotherapy (chemo): results of COU-AA-301, a randomized double-blind placebo-controlled Phase III study. Ann. Oncol. 21(Suppl. 8), VIII1-VIII12 (2010) (Abstract
8. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363(5), 411-422 (2010
9. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711-723 (2010
10. Kantoff PW, Schuetz TJ, Blumenstein BA et al. Overall survival analysis of a Phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J. Clin. Oncol. 28(7), 1099-1105 (2010
11. Rini BI. Technology evaluation: APC- 8015, Dendreon. Curr. Opin. Mol. Ther. 4(1), 76-79 (2002 (Pubitemid 34649797)
12. Patel PH, Kockler DR. Sipuleucel-T: a vaccine for metastatic, asymptomatic, androgen-independent prostate cancer. Ann. Pharmacother. 42(1), 91-98 (2008
13. Burch PA, Breen JK, Buckner JC et al. Priming tissue-specific cellular immunity in a Phase I trial of autologous dendritic cells for prostate cancer. Clin. Cancer Res. 6(6), 2175-2182 (2000 (Pubitemid 30399182)
14. Small EJ, Fratesi P, Reese DM et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J. Clin. Oncol. 18(23), 3894-3903 (2000
15. Small EJ, Schellhammer PF, Higano CS et al. Placebo-controlled Phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J. Clin. Oncol. 24(19), 3089-3094 (2006 (Pubitemid 46638945)
16. Madan RA, Arlen PM, Mohebtash M, Hodge JW, Gulley JL. Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. Expert Opin. Investig. Drugs 18(7), 1001-1011 (2009
17. Essajee S, Kaufman HL. Poxvirus vaccines for cancer and HIV therapy. Expert Opin. Biol. Ther. 4(4), 575-588 (2004 (Pubitemid 38480556)
18. Kaufman H, Wang W, Manola J et al. Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J. Clin. Oncol. 22(11), 2122-2132 (2004 (Pubitemid 41095145)
19. Hodge JW, Sabzevari H, Yafal AG, Gritz L, Lorenz MG, Schlom J. A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res. 59(22), 5800-5807 (1999
20. Aarts WM, Schlom J, Hodge JW. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity. Cancer Res. 62(20), 5770-5777 (2002 (Pubitemid 35204734)
21. Grosenbach DW, Barrientos JC, Schlom J, Hodge JW. Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects. Cancer Res. 61(11), 4497-4505 (2001 (Pubitemid 32685780)
22. Arlen PM, Skarupa L, Pazdur M et al. Clinical safety of a viral vector based prostate cancer vaccine strategy. J. Urol. 178(4 Pt 1), 1515-1520 (2007 (Pubitemid 47368382)
23. Gulley JL, Arlen PM, Madan RA et al. Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol. Immunother. 59(5), 663-674 (2010
24. Schlom J, Gulley JL, Arlen PM. Paradigm shifts in cancer vaccine therapy. Exp. Biol. Med. 233(5), 522-534 (2008 (Pubitemid 351657353)
25. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat. Rev. Immunol. 8(1), 59-73 (2008
26. Galetto A, Buttiglieri S, Forno S, Moro F, Mussa A, Matera L. Drug- and cell-mediated antitumor cytotoxicities modulate cross-presentation of tumor antigens by myeloid dendritic cells. Anticancer Drugs 14(10), 833-843 (2003 (Pubitemid 38339789)
27. Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin. Cancer Res. 11(18), 6713-6721 (2005 (Pubitemid 41339014)
28. Weber JS, O'Day S, Urba W et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. J. Clin. Oncol. 26(36), 5950-5956 (2008
29. Phan GQ, Yang JC, Sherry RM et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl Acad. Sci. USA 100(14), 8372-8377 (2003 (Pubitemid 36842552)
30. Stein WD, Figg WD, Dahut W et al. Tumor growth rates derived from data for patients in a clinical trial correlate strongly with patient survival: a novel strategy for evaluation of clinical trial data. Oncologist 13(10), 1046-1054 (2008
31. Fojo A, Stein W, Wilkerson J, Bates S. Kinetic analysis of breast tumor decay and growth following ixabepilone plus capecitabine (IXA + CAP) versus capecitabine alone (CAP) to discern whether the superiority of the combination is a result of slower growth, enhanced tumor cell kill, or both. J. Clin. Oncol. 28(15s), 1096 (2010) (Abstract
32. Wilkerson J, Stein W, Kim S et al. Validation of a kinetic analysis of renal cancer regression and growth following treatment with sunitinib and interferon-a (IFN-a): Analysis of the pivotal randomized trial. J. Clin. Oncol. 28(15s), 4597 (2010) (Abstract
33. Stein WD, Gulley J, Schlom J et al. Tumor regression and growth rates determined in five intramural NCI prostate cancer trials. The growth rate as an indicator of therapeutic efficacy. Clin. Cancer Res. 17(4), 907-917 (2010
34. Gulley J, Stein W, Schlom J et al. A retrospective analysis of intramural NCI prostate cancer trials: progress made and insights gleaned. J. Clin. Oncol. 28(15s), 4657 (2010) (Abstract
35. Lucas A, Petrylak DP. The case for early chemotherapy for the treatment of metastatic disease. J. Urol. 176(6 Pt 2), S72-S75 (2006 (Pubitemid 44649300)
36. Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 71(Suppl. 3), 1098-1109 (1993 (Pubitemid 23049638)
37. Scher H, Chi K, De Wit R et al. Docetaxel (D) plus high-dose calcitriol versus D plus prednisone (P) for patients (pts) with progressive castration-resistant prostate cancer (CRPC): results from the Phase III ASCENT2 trial. J. Clin. Oncol. 28(15s) (2010) (Abstract 4509
38. Kelly W, Halabi S, Carducci M et al. A randomized, double-blind, placebo-controlled Phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): survival results of CALGB 90401. J. Clin. Oncol. 28(18s) (2010) (Abstract LBA4511
39. Small E, Demkow T, Gerritsen W et al. A Phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (CRPCProgram and Abstracts of the Genitourinary Cancers Symposium. Orlando, FL, USA (2009) (Abstract 7
40. Sartor A, Oudard S, Ozguroglu M et al. Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: final results of a multinational Phase III trial (TROPICProgram and Abstracts of the Genitourinary Cancers Symposium. San Francisco, CA, USA (2010) (Abstract 9
41. Attard G, Reid AH, Yap TA et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J. Clin. Oncol. 26(28), 4563-4571 (2008
42. Danila DC, Morris MJ, de Bono JS et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J. Clin. Oncol. 28(9), 1496-1501 (2010
43. Shah S, Ryan C. Abiraterone acetate for castration resistant prostate cancer. Expert Opin. Investig. Drugs 19(4), 563-570 (2010
44. Halabi S, Small EJ, Kantoff PW et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J. Clin. Oncol. 21(7), 1232-1237 (2003 (Pubitemid 46606398)
45. Madan RA, Mohebtash M, Schlom J, Gulley JL. Therapeutic vaccines in metastatic castration-resistant prostate cancer: principles in clinical trial design. Expert Opin. Biol. Ther. 10(1), 19-28 (2010
46. Higano CS, Corman JM, Smith DC et al. Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer 113(5), 975-984 (2008
47. Fu T, Shen Y, Fujimoto S. Tumor-specific CD4(+) suppre T-cell clone capable of inhibiting rejection of syngeneic sarcoma in A/J. mice. Int. J. Cancer 87(5), 680-687 (2000 (Pubitemid 30620411)
48. Ghiringhelli F, Larmonier N, Schmitt E et al. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur. J. Immunol. 34(2), 336-344 (2004 (Pubitemid 39255944)
49. Curiel TJ, Coukos G, Zou L et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10(9), 942-949 (2004 (Pubitemid 39273735)
50. Sato E, Olson SH, Ahn J et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl Acad. Sci. USA 102(51), 18538-18543 (2005 (Pubitemid 43011261)
51. Kawaida H, Kono K, Takahashi A et al. Distribution of CD4+CD25high regulatory T-cells in tumor-draining lymph nodes in patients with gastric cancer. J. Surg. Res. 124(1), 151-157 (2005 (Pubitemid 40269816)
52. Woo EY, Chu CS, Goletz TJ et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 61(12), 4766-4772 (2001 (Pubitemid 32691889)
53. Piccirillo CA, Shevach EM. Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells. J. Immunol. 167(3), 1137-1140 (2001 (Pubitemid 32703105)
54. Woo EY, Yeh H, Chu CS et al. Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J. Immunol. 168(9), 4272-4276 (2002 (Pubitemid 34441324)
55. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor a-chains (CD25Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155(3), 1151-1164 (1995
56. Morse MA, Clay TM, Mosca P, Lyerly HK. Immunoregulatory T cells in cancer immunotherapy. Expert Opin. Biol. Ther. 2(8), 827-834 (2002 (Pubitemid 36033249)
57. Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 101(5), 455-458 (2000
58. Madan R, Vergati M, Cereda V et al. Changes in regulatory T cell function and overall survival in metastatic castration resistant prostate cancer (mCRPC) patients treated with a vector-based vaccine. Presented at: AACR Annual Meeting. Denver, CO, USA, 18-22 April 2009 (Poster 726
59. Vergati M, Cereda V, Madan RA et al. Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination. Cancer Immunol. Immunother. 60(2), 197-206 (2010
60. Halabi S, Vogelzang NJ, Kornblith AB et al. Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. J. Clin. Oncol. 26(15), 2544-2549 (2008
61. Higano C, Saad F, Somer B et al. A Phase III trial of GVAX immunotherapy for prostate cancer versus docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer (CRPCProgram and Abstracts of the Genitourinary Cancers Symposium. Orlando, FL, USA (2009) (Abstract LBA150
62. von Mehren M, Arlen P, Gulley J et al. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clin. Cancer Res. 7(5), 1181-1191 (2001 (Pubitemid 32708668)
63. Armstrong AJ, Garrett-Mayer ES, Yang YC, de Wit R, Tannock IF, Eisenberger M. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin. Cancer Res. 13(21), 6396-6403 (2007 (Pubitemid 350075029)
64. Scher HI, Halabi S, Tannock I et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J. Clin. Oncol. 26(7), 1148-1159 (2008
65. Madan RA, Gulley JL, Schlom J et al. Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy. Clin. Cancer Res. 14(14), 4526-4531 (2008
66. Longo DL. New therapies for castration-resistant prostate cancer. N. Engl. J. Med. 363(5), 479-481 (2010
67. Boehm AL, Higgins J, Franzusoff A, Schlom J, Hodge JW. Concurrent vaccination with two distinct vaccine platforms targeting the same antigen generates phenotypically and functionally distinct T-cell populations. Cancer Immunol. Immunother. 59(3), 397-408 (2010
68. McNeel DG, Dunphy EJ, Davies JG et al. Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. J. Clin. Oncol. 27(25), 4047-4054 (2009
69. Su Z, Dannull J, Yang BK et al. Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. J. Immunol. 174(6), 3798-3807 (2005 (Pubitemid 40354093)
70. Aragon-Ching JB, Williams KM, Gulley JL. Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer. Front. Biosci. 12, 4957-4971 (2007
71. Drake CG, Doody AD, Mihalyo MA et al. Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell 7(3), 239-249 (2005 (Pubitemid 40568683)
72. Garnett CT, Schlom J, Hodge JW. Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement. Clin. Cancer Res. 14(11), 3536-3544 (2008
73. Chakraborty M, Abrams SI, Coleman CN, Camphausen K, Schlom J, Hodge JW. External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res. 64(12), 4328-4337 (2004 (Pubitemid 38802440)
74. Hoos A, Eggermont AM, Janetzki S et al. Improved endpoints for cancer immunotherapy trials. J. Natl Cancer Inst. 102(18), 1388-1397 (2010
75. Palanisamy N, Ateeq B, Kalyana- Sundaram S et al. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat. Med. 16(7), 793-798 (2010
76. Sharifi N, Hamada A, Sissung T et al. A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer. BJU Int. 102(5), 617-621 (2008
77. Kantoff P, Higano CS, Berger ER. Updated survival results of the IMPACT trial of sipuleucel-T for metastatic castration-resistant prostate cancer (CRPCPrograms and Abstracts of the 2010 Genitourinary Cancers Symposium. San Francisco, CA, USA (2010) (Abstract